Can I be prescribed medication for overactive bladder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Medication Be Prescribed for Overactive Bladder?

Yes, you can be prescribed medication for overactive bladder, specifically either antimuscarinic medications or beta-3 agonists as second-line therapy after behavioral interventions, with beta-3 agonists typically preferred first due to their superior safety profile, particularly regarding cognitive risks. 1

Treatment Algorithm

First-Line: Behavioral Therapies (Always Start Here)

  • Behavioral therapies including bladder training, delayed voiding, pelvic floor muscle training, urge suppression techniques, fluid management, weight loss, and caffeine reduction should be offered to all patients with OAB symptoms 2
  • These interventions have excellent safety profiles with few adverse effects and high risk-benefit ratios, though success depends heavily on patient adherence 1
  • Bladder training has been extensively studied and is recommended based on strong evidence 1

Second-Line: Pharmacologic Management

Beta-3 Agonists (Preferred Initial Medication):

  • Beta-3 agonists like mirabegron (50 mg once daily) or vibegron (75 mg once daily) are typically preferred before antimuscarinic medications 1, 3
  • These medications improve urgency urinary episodes, voiding frequency, and urgency urinary incontinence compared to placebo 1
  • They have a more favorable side effect profile than antimuscarinics, particularly no increased risk of dementia or cognitive impairment 3
  • Mirabegron should be taken with water, swallowed whole (not crushed), and can be taken with or without food 4

Antimuscarinic Medications (Alternative Second-Line):

  • Available antimuscarinics include darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium 2
  • These medications are effective for improving urgency, frequency, and urgency urinary incontinence 1
  • Critical warning: There is evidence suggesting an association between antimuscarinic medications and increased risk of all-cause dementia and Alzheimer's disease, which may be cumulative and dose-dependent 1
  • You must discuss this potential cognitive risk with all patients, especially elderly individuals, before prescribing antimuscarinics for chronic use 1

Important Contraindications and Cautions

Absolute Contraindications for Antimuscarinics:

  • Narrow-angle glaucoma 1, 5
  • Impaired gastric emptying 1
  • History of urinary retention 1, 5

Use with Extreme Caution in:

  • Patients with diabetes 1
  • Elderly patients (due to cognitive risks with antimuscarinics) 1
  • Patients with bladder outlet obstruction (increased risk of urinary retention) 4

For Beta-3 Agonists:

  • Monitor blood pressure, as these medications may increase blood pressure or worsen existing hypertension 4
  • Use caution in patients with liver or kidney problems 4

Combination and Optimization Strategies

If Monotherapy Fails:

  • You may combine behavioral therapy with pharmacotherapy 1
  • Combination of a beta-3 agonist with an antimuscarinic may be considered for patients refractory to monotherapy 2
  • If one antimuscarinic fails due to inadequate symptom control or unacceptable side effects, try dose modification or switch to a different antimuscarinic or beta-3 agonist 1
  • Do not abandon antimuscarinic therapy after just one medication trial fails 1

Dosing Considerations:

  • Tolterodine can be taken with or without food, at the same times each day 5
  • Extended-release formulations may provide better tolerability than immediate-release versions 1

Common Side Effects to Counsel Patients About

Antimuscarinics:

  • Dry mouth, constipation, dry eyes, blurred vision, dyspepsia, UTI, and urinary retention 2
  • Cognitive impairment and dementia risk (long-term use) 1

Beta-3 Agonists:

  • Increased blood pressure 4
  • Potential urinary retention in patients with bladder outlet obstruction 4
  • Risk of angioedema (rare) 4

When to Refer for Advanced Therapies

If behavioral therapies and oral medications fail to provide adequate symptom control, consider referral to urology or urogynecology for:

  • Intradetrusor onabotulinumtoxinA injections 1
  • Peripheral tibial nerve stimulation (PTNS) 1
  • Sacral neuromodulation (SNS) 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Overactive Bladder Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Overactive Bladder Treatment with Gemtesa (Vibegron)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.